2 hrs ago
Hope for breast cancer patients
VICTORIAN breast cancer patients will get access to world-first clinical trials with a big research funding boost unveiled today.
Fri Mar 14, 2014
Tumor infiltrating lymphocytes is prognostic and predictive for...
We have previously shown the prognostic importance of tumor infiltrating lymphocytes in newly-diagnosed triple-negative breast cancer using tumor samples from a large clinical trial cohort.
Tue Mar 11, 2014
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in ...
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.
Fri Mar 07, 2014
Sunitinib in combination with trastuzumab for the treatment of...
This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer .
Thu Mar 06, 2014
Fri Feb 28, 2014
Galena Biopharma Bolsters NeuVax(TM) (nelipepimut-S) Intellectual...
The patent provides NeuVax the exclusivity for this indication until 2028, not including any patent term extensions.
Wed Feb 26, 2014
Epigenetic silencing of miR-375 induces trastuzumab resistance in...
Resistance to humanized monoclonal erbB2/HER2 antibody, trastuzumab , has become a pivotal obstacle for targeted therapy of HER2-positive breast cancers.
Genentech's Distribution of Prescribing Information to...
On January 31, 2014, Phigenix, Inc. filed a lawsuit in federal district court in Georgia alleging that the sale and use of the drug Kadcyla by Genentech, Inc. infringed U.S. Patent No.
Thu Feb 20, 2014
Applied Clinical Trials
Oncothyreon and Array BioPharma Announce Initiation of Phase 1b Trial ...
ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.
Tue Feb 18, 2014
Natural compound attacks HER2 positive breast cancer cells
A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report.